Literature DB >> 31057627

On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve.

Hua Ma1, Susan Halabi2, Aiyi Liu3.   

Abstract

BACKGROUND: Evaluation of diagnostic assays and predictive performance of biomarkers based on the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) are vital in diagnostic and targeted medicine. The partial area under the curve (pAUC) is an alternative metric focusing on a range of practical and clinical relevance of the diagnostic assay. In this article, we adopt and extend the min-max method to the estimation of the pAUC when multiple continuous scaled biomarkers are available and compare the performances of our proposed approach with existing approaches via simulations.
METHODS: We conducted extensive simulation studies to investigate the performance of different methods for the combination of biomarkers based on their abilities to produce the largest pAUC estimates. Data were generated from different multivariate distributions with equal and unequal variance-covariance matrices. Different shapes of the ROC curves, false positive fraction ranges, and sample size configurations were considered. We obtained the mean and standard deviation of the pAUC estimates through re-substitution and leave-one-pair-out cross validation.
RESULTS: Our results demonstrate that the proposed method provides the largest pAUC estimates under the following three important practical scenarios: (1) multivariate normally distributed data for non-diseased and diseased participants have unequal variance-covariance matrices; or (2) the ROC curves generated from individual biomarker are relative close regardless of the latent normality distributional assumption; or (3) the ROC curves generated from individual biomarker have straight-line shapes.
CONCLUSIONS: The proposed method is robust and investigators are encouraged to use this approach in the estimation of the pAUC for many practical scenarios.

Entities:  

Keywords:  ROC curve; area under the curve (AUC); combination of biomarkers; leave-one-pair-out cross validation; min-max method; partial area under the curve (pAUC); re-substitution

Year:  2019        PMID: 31057627      PMCID: PMC6499396          DOI: 10.1155/2019/8953530

Source DB:  PubMed          Journal:  J Probab Stat        ISSN: 1687-952X


  25 in total

1.  A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets.

Authors:  Dong D Zhang; Xia-Hua Zhou; Daniel H Freeman; Jean L Freeman
Journal:  Stat Med       Date:  2002-03-15       Impact factor: 2.373

2.  Partial AUC estimation and regression.

Authors:  Lori E Dodd; Margaret S Pepe
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

3.  ROC curve analysis for biomarkers based on pooled assessments.

Authors:  David Faraggi; Benjamin Reiser; Enrique F Schisterman
Journal:  Stat Med       Date:  2003-08-15       Impact factor: 2.373

4.  Combining diagnostic test results to increase accuracy.

Authors:  M S Pepe; M L Thompson
Journal:  Biostatistics       Date:  2000-06       Impact factor: 5.899

5.  On linear combinations of biomarkers to improve diagnostic accuracy.

Authors:  Aiyi Liu; Enrique F Schisterman; Yan Zhu
Journal:  Stat Med       Date:  2005-01-15       Impact factor: 2.373

6.  Combining predictors for classification using the area under the receiver operating characteristic curve.

Authors:  Margaret Sullivan Pepe; Tianxi Cai; Gary Longton
Journal:  Biometrics       Date:  2006-03       Impact factor: 2.571

7.  Nonparametric statistical inference method for partial areas under receiver operating characteristic curves, with application to genomic studies.

Authors:  Yaohua He; Michael Escobar
Journal:  Stat Med       Date:  2008-11-10       Impact factor: 2.373

8.  A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies.

Authors:  Y Huang; M S Pepe
Journal:  Biometrics       Date:  2009-12       Impact factor: 2.571

9.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; San-San Ou; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

10.  The Optimal Linear Combination of Multiple Predictors Under the Generalized Linear Models.

Authors:  Hua Jin; Ying Lu
Journal:  Stat Probab Lett       Date:  2009-11-15       Impact factor: 0.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.